Sarah Hijazi

Dr. Sarah Hijazi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in The FEBS Journal
Verified
Journal Article
Open access
SHSarah Hijazi
Sarah Hijazi
MCMonica Cozzi
Monica Cozzi
SASomayeh Asgharpour
Somayeh Asgharpour
OBOmar De Bei
Omar De Bei
SFSerena Faggiano
Serena Faggiano
Stefano BettatiStefano Bettati
Stefano Bettati
Siderophore production, along with heme scavenging by hemophores, is one of the main mechanisms exploited by bacteria to achieve an adequate iron supply. Staphylococcus aureus produces two main siderophores, staphyloferrin A (SA) and staphyloferrin B (SB), with the latter produced only by the most invasive, coagulase‐positive S. aureus strains. Along the seven steps of the SB biosynthetic pathway, N ‐(2‐amino‐2‐carboxyethyl)‐ l ‐glutamate synthase (SbnA) catalyzes the crucial formation of the intermediate N ‐(2‐amino‐2‐carboxyethyl)‐ l ‐glutamate from O‐phospho‐L‐serine and glutamate. Our functional characterization of the enzyme highlighted that citrate inhibits SbnA with an inhibitory constant ( K i ) in the order of magnitude of the physiological concentration of the metabolite. We searched for inhibitors of SbnA within citrate analogues and identified 2‐phenylmaleic acid (2‐PhMA) as the best hit, with a K i of 16 ± 2 μ m and a mechanism of inhibition that is competitive with O‐phospho‐L‐serine for active site binding. The methyl ester of 2‐PhMA at a 2 m m concentration was effective in inhibiting siderophore biosynthesis in S. aureus . These results pave the way for the discovery of promising inhibitors of iron acquisition that might find application as innovative antimicrobials.

3 March 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
SMSara Maestrini
Sara Maestrini
ADAurora Diotallevi
Aurora Diotallevi
SHSarah Hijazi
Sarah Hijazi
SHSara Habouria
Sara Habouria
EFemanuela frangipani
emanuela frangipani
LGLuca Galluzzi
Luca Galluzzi
Leishmania spp., the causative agents of leishmaniasis, pose significant global health threats, with visceral leishmaniasis being the most severe and fatal form. The increasing drug resistance in the treatment of leishmaniasis emphasizes the urgent need for novel therapeutic approaches. One promising strategy involves targeting essential cellular mechanisms such as nutrient acquisition, particularly iron, which is critical for energy metabolism and signal transduction. Leishmania spp. cannot synthesize heme de novo and rely on host-derived iron and heme for survival and pathogenicity. Gallium [Ga(III)] is an iron [Fe(III)]-mimetic molecule that has emerged as a promising antimicrobial agent, offering a novel approach to combat infections, mainly by replacing Fe(III) in redox enzymes thereby disrupting essential metabolic pathways and impairing microbial viability. In this study, the antiparasitic activity of Ga (III)-protoporphyrin IX (GaPPIX) was tested against Leishmania major and Leishmania infantum , both in promastigotes and intracellular amastigotes. Our results demonstrate that GaPPIX inhibits the viability of both species, specifically targeting the enzymatic activity of cytochrome c oxidase, with a higher sensitivity observed in L. major . The inhibitory effect is reversed by hemin, suggesting specificity for Leishmania heme-dependent cellular processes and a possible cytostatic action. Moreover, we found that GaPPIX can effectively synergize with miltefosine. This feature, coupled with its minimal toxicity toward human cells, makes GaPPIX a good candidate to be potentially developed as a novel anti- Leismania agent. IMPORTANCE: This study is significant as it addresses a critical challenge in leishmaniasis management, namely, the increasing incidence of drug resistance and toxicity, compounded by the scarcity of effective therapeutic options. We demonstrate that GaPPIX, a heme-mimetic compound, exhibits potent antiparasitic activity against both Leishmania major and Leishmania infantum , while displaying minimal cytotoxicity toward human cells, underscoring its potential as a safe and targeted therapeutic candidate. Importantly, the ability of GaPPIX to synergize with the first-line drug miltefosine highlights its translational relevance in combination therapies, which are essential for overcoming resistance and improving treatment efficacy. Collectively, these findings advance GaPPIX as a promising approach for the development of innovative therapeutics against a neglected but globally significant disease.

Verified
Journal Article
Open access
PDF file
FGFrancesco Guggino
Francesco Guggino
SHSarah Hijazi
Sarah Hijazi
RMREBECCA MARTEDI'
REBECCA MARTEDI'
VCValeria Buoli Comani
Valeria Buoli Comani
JDJole Maria Lucia D’Angelo
Jole Maria Lucia D’Angelo
BCBarbara Campanini
Barbara Campanini
Cysteine biosynthesis is increasingly recognized as a critical determinant of bacterial virulence, highlighting this pathway as a promising reservoir of novel antimicrobial targets. In Pseudomonas aeruginosa, however, the molecular basis of cysteine production has only recently begun to emerge. Here, we identify PA3816 as the major P. aeruginosa serine acetyltransferase (PaCysE), the enzyme responsible for generating the activated serine intermediate that feeds O-acetylserine sulfhydrylase-mediated cysteine synthesis. Through a combination of biochemical and genetic approaches, we demonstrate that PaCysE efficiently catalyzes L-serine acetylation in vitro, and in turn, deletion mutants exhibit cysteine auxotrophy, underscoring its essential contribution to O-acetylserine production. Notably, PaCysE is less sensitive to feedback inhibition by cysteine and does not appear to form the canonical cysteine synthase complex, suggesting a regulatory architecture that diverges from well-characterized orthologs. Loss of PaCysE function has broad physiological consequences, including enhanced biofilm formation, reduced pyocyanin production, and attenuated infectivity in an animal model, linking cysteine biosynthesis directly to pathogen fitness. Finally, we identify a thiazole derivative that inhibits PaCysE activity (IC50 ≈ 30 µM) and suppresses bacterial growth in a cysteine-dependent manner, providing a proof-of-concept for therapeutically targeting this pathway.

29 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SHSarah Hijazi
Sarah Hijazi
FMFrancesco Marchesani
Francesco Marchesani
MMMarialaura Marchetti
Marialaura Marchetti
VCValeria Buoli Comani
Valeria Buoli Comani
PBPaul Brear
Paul Brear
Stefano BettatiStefano Bettati
Stefano Bettati
Infections caused by Staphylococcus aureus are closely linked to its ability to secure essential nutrients, including iron, which is extracted from the heme of human hemoglobin (Hb) through the iron-regulated surface determinant (Isd) system. The compound 4-[[2-[[5- (1H-indol-3-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetyl]amino]benzoate (C35) was recently identified as a new potential antimicrobial agent for its ability to bind Hb and hamper its interaction with the staphylococcal hemophore IsdB in vitro . Here, we show that C35 inhibits S. aureus growth by specifically targeting the hemophore-driven iron acquisition system. Our findings confirm both the potential of C35 as a first-in-class protein-protein interaction inhibitor with antimicrobial activity, and the effectiveness of targeting hemophores as a strategy to inhibit S. aureus growth. To gain information for drug discovery purposes, the X-ray structure of Hb in the presence of the compound was solved. Unexpectedly, we discovered that, rather than the predicted binding pose, the molecule binds to tetrameric Hb in a cleft between the alpha subunits, stabilizing an R2 relaxed Hb conformation. This triggered further investigation of the effect of C35 on Hb functional properties, which showed a pronounced left-shift activity on oxygen binding curve (i.e., it strongly increases the Hb oxygen affinity). These results highlight C35 as a promising dual-acting compound with both antimicrobial activity and the ability to modulate Hb function through non-covalent stabilization of a high-affinity state. Author Summary: Staphylococcus aureus is a dangerous bacterium that can cause severe infections in humans. To grow and survive it needs iron, which it steals from our red blood cells by taking it from hemoglobin, the protein that carries oxygen in the blood. In this study, we focused on a small molecule, called C35, that blocks the interaction between hemoglobin and a key bacterial protein involved in heme acquisition. We found that C35 strongly inhibits the growth of S. aureus when hemoglobin is the only available source of iron, showing a potential new method to starve the pathogen and consequently fight the infection. Surprisingly, we also found that C35 increases the affinity of hemoglobin for oxygen. This dual action makes C35 a unique molecule for future therapeutic development, with potential applications both as a new antimicrobial agent and in the treatment of diseases related to hemoglobin function.